Introducing Kardia 12L: The first of its kind 12-lead portable ECG | Learn More

AliveCor Logo

Our Products

AFib Screening
Data Integration Solutions
KardiaCare Plus
KardiaComplete
Kardia 12L

New

KardiaMobile 6L
AliveCor K1000
KardiaStation
KardiaPro
Kardia ECG Devices

Our Solutions

Health Systems
Clinical Trials
Payors
Employers
OEMs
Veterans Affairs

About

Leadership
Mission
Clinical Research
Our AI
For Consumers
The Human Component Film
Newsroom
(855) 338-8800
AliveCor Logo
AliveCor Logo
  • Instagram
  • Facebook
  • Twitter
  • LinkedIn
    • (855) 338-8800
    • Mission
    • Careers
    • Research
    • Newsroom
    • FAQs
    • User Manuals
    • Compatibility
    • Shipping
    • (855) 338-8800
    • KardiaMobile Card
    • KardiaMobile 6L
    • KardiaMobile
    • KardiaCare
    • International
  • Instagram
  • Facebook
  • Twitter
  • LinkedIn
  • Privacy Policy
  • Security
  • Telehealth Informed Consent
  • Terms
  • Accessibility

©2024 AliveCor, Inc. All Rights Reserved. Patents www.alivecor.com/patents. AliveCor and Kardia are trademarks of AliveCor, Inc. in the United States and other countries. Apple is a trademark of Apple, Inc. registered in the U.S. and other countries. App Store is a service mark of Apple, Inc. Android is a trademark of Google Inc. Google Play is a trademark of Google Inc.

Leading the Future of Heart Care

Our mission comes to life through the people who depend on our products to manage their heart health every day. Cardiovascular disease remains the leading cause of death globally, and is responsible for more than $1 billion in annual healthcare spending. More importantly, it takes a tremendous toll on people’s lives and the lives of their caregivers, families, and friends.

Prevention is critical for reversing this trend and enabling people to live longer, healthier lives. Our FDA-cleared Kardia™ devices deliver clinical-quality ECGs capable of identifying some of the most common and dangerous irregular heart rhythms, including atrial fibrillation, Bradycardia, Tachycardia, Sinus Rhythm with PVCs, Sinus Rhythm with Wide QRS, and Sinus Rhythm with SVE. This places the power of advanced AI technology directly in our customers’ hands, giving them answers and peace of mind. Additionally, healthcare providers have a way to capture their patients’ arrhythmias, leading to earlier diagnosis and improving clinical decision-making.

Learn more about how we’re advancing the future of heart care to benefit people with cardiovascular disease and healthcare providers in the video above.

feedback
""Early diagnosis means early treatment and, thanks to digital technology and AI, we’re able to make better and faster diagnoses. [KardiaMobile]accelerated definite therapy for me – I recommend it to my patients.""
Dr. Cleveland Francis

Cardiologist and patient